Asset profile
ABP 938
Protein / enzyme therapeutic
Evidence outlook · lead readout
NCT04270747 · Neovascular (Wet) Age-related Macular Degeneration (AMD)
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT04270747: This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
31 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 31 same-indication; 10 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| ABP 938: this drug | Phase 3 | Protein / enzyme therapeutic | VEGF-A / VEGF-B / PlGF | ||
| Aflibercept (Eylea) | Approved | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | ||
| Avacincaptad Pegol (Izervay) | Approved | Rna Aptamer | Complement C5 | ||
| Brolucizumab-Dbll | Approved | Monoclonal antibody | VEGF-A | ||
| Chloroprocaine | Approved | Small molecule | Voltage-gated sodium channels (Nav) on sensory nerve membranes | ||
| Faricimab | Approved | Multispecific antibody | Angiopoietin-2 / VEGF-A | ||
| Pegaptanib (Macugen) | Approved | Small molecule | VEGF-A | ||
| Pegcetacoplan Ophthalmic (Syfovre) | Approved | Peptide | Complement C3, Complement C3 / C3b | ||
| Ranibizumab (Lucentis) | Approved | Monoclonal antibody | VEGF-A | ||
| Verteporfin | Approved | Small molecule | Benzoporphyrin-derivative photosensitizer for photodynamic therapy | ||
| Visudyne | Approved | Small molecule | Photosensitizing agent (photodynamic therapy) | ||
| ABBV-RGX-314 | Phase 3 | Gene therapy / editing | VEGF-A | ||
| ANX007 | Phase 3 | Monoclonal antibody | Complement C1q | ||
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | ||
| CKD-701 | Phase 3 | Monoclonal antibody | VEGF-A | ||
| HLX04-O | Phase 3 | Monoclonal antibody | VEGF-A |
…and 16 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
July 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.